Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.69 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.59 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.51 |
| ▸ | RARB | P10826 | 2/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623897 | 1.00 | MCL1 (0.69) | MCL1PTPN11KAT8TP53TSHR | |
| SCHEMBL9285957 | 0.97 | MCL1 (0.66) | MCL1PTPN11KAT8TP53TSHR | |
| SCHEMBL11694352 | 0.95 | PTPN11 (0.67) | MCL1PTPN11KAT8TP53TSHR | |
| SCHEMBL4653931 | 0.95 | PTPN11 (0.67) | MCL1PTPN11KAT8TP53TSHR | |
| SCHEMBL29623919 | 0.95 | PTPN11 (0.67) | MCL1PTPN11KAT8TP53TSHR | |
| SCHEMBL29623817 | 0.95 | PTPN11 (0.67) | MCL1PTPN11KAT8TP53TSHR | |
| SCHEMBL1576902 | 0.95 | PTPN11 (0.67) | MCL1PTPN11KAT8TP53TSHR | |
| SCHEMBL223621 | 0.95 | PTPN11 (0.67) | MCL1PTPN11KAT8TP53TSHR | |
| SCHEMBL538445 | 0.93 | MCL1 (0.61) | MCL1PTPN11KAT8 | |
| SCHEMBL16363214 | 0.88 | MCL1 (0.70) | MCL1PTPN11KAT8TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144729-A1 | A CLEANSING COMPOSITION | L'OREAL (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4611719-A1 | A CLEANSING COMPOSITION | L'OREAL (FR) | 2025-09-10 | — | — | EP | claimed |
| CN-120076784-A | Cleaning composition | 莱雅公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2024092386-A1 | A CLEANSING COMPOSITION | L'OREAL (FR) | 2024-05-10 | — | — | WO | claimed |
| US-8974804-B2 | Composition in the form of an oil-in-water emulsion and uses thereof | L'OREAL (FR) | 2015-03-10 | — | — | US | claimed |
| US-20120301414-A1 | COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION AND USES THEREOF | L'OREAL (FR) | 2012-11-29 | — | — | US | claimed |
| EP-1415645-B1 | Composition in the form of an oil-in-water emulsion and its cosmetic uses | OREAL (FR) | 2007-10-03 | — | — | EP | claimed |
| US-20040166128-A1 | Composition in the form of an oil-in-water emulsion and uses thereof | L'OREAL (FR) | 2004-08-26 | — | — | US | claimed |
| CN-1101180-C | Cosmetics and/or composition for treating skin disease and use thereof | OREAL (FR) | 2003-02-12 | — | — | CN | claimed |
| EP-0987011-B1 | Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its use | OREAL (FR) | 2002-07-17 | — | — | EP | claimed |
| EP-0031561-B1 | A RECTALLY ADMINISTERED SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT | MERCK & CO. INC. (US) | 1985-04-10 | — | — | EP | claimed |
| US-4470980-A | Method of increasing oral absorption of β-lactam antibiotics | INTERX RESEARCH CORP. (US) | 1984-09-11 | — | — | US | claimed |
| US-4464363-A | HYDROXY ARYL- OR HYDROXY ARALKYL ACIDS OR SALTS | MERCK & CO., INC. (US) | 1984-08-07 | — | — | US | claimed |
| US-4462991-A | POLYPEPTIDE ADJUVANTS OF CARBOXY- OR SULFOSUBSTITUTED PHENOLS | INTERX RESEARCH CORP. (US) | 1984-07-31 | — | — | US | claimed |
| US-4459295-A | Method of increasing oral absorption of glycosidic and related antibiotics | INTERX RESEARCH CORPORATION (US) | 1984-07-10 | — | — | US | claimed |
| US-4406896-A | ANTIBIOTICS, ACIDS, HYDROXY | MERCK & CO., INC. (US) | 1983-09-27 | — | — | US | claimed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0035770-A2 | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-16 | — | — | EP | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301414-A1 | COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION AND USES THEREOF | PLOD3, CUTA, LOXL1 | MCL1 2887/4885PTPN11 3469/4885KAT8 1397/4885 |
| US-20040166128-A1 | Composition in the form of an oil-in-water emulsion and uses thereof | PLOD3, CUTA, LOXL1 | MCL1 2887/4885PTPN11 3469/4885KAT8 1397/4885 |
| US-20260144729-A1 | A CLEANSING COMPOSITION | SMURF1, CUTA, S100B | MCL1 4475/4885PTPN11 3869/4885KAT8 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.